Effect of Fructooligosaccharides Supplementation on the Gut Microbiota in Human: A Systematic Review and Meta-Analysis
- PMID: 36014803
- PMCID: PMC9413759
- DOI: 10.3390/nu14163298
Effect of Fructooligosaccharides Supplementation on the Gut Microbiota in Human: A Systematic Review and Meta-Analysis
Abstract
Background: Numerous studies have investigated the effects of the supplementation of fructooligosaccharides (FOS) on the number of bacteria in the gut that are good for health, but the results have been inconsistent. Additionally, due to its high fermentability, supplementation of FOS may be associated with adverse gastrointestinal symptoms such as bloating and flatulence. Therefore, we assessed the effects of FOS interventions on the composition of gut microbiota and gastrointestinal symptoms in a systematic review and meta-analysis. Design: All randomized controlled trials published before 10 July 2022 that investigated the effects of FOS supplementation on the human gut microbiota composition and gastrointestinal symptoms and met the selection criteria were included in this study. Using fixed or random-effects models, the means and standard deviations of the differences between the two groups before and after the intervention were combined into weighted mean differences using 95% confidence intervals (CIs). Results: Eight studies containing 213 FOS supplements and 175 controls remained in this meta-analysis. Bifidobacterium spp. counts significantly increased during FOS ingestion (0.579, 95% CI: 0.444−0.714) in comparison with that of the control group. Subgroup analysis showed greater variation in Bifidobacterium spp. in adults (0.861, 95% CI: 0.614−1.108) than in infants (0.458, 95% CI: 0.297−0.619). The increase in Bifidobacterium spp. counts were greater in the group with an intervention duration greater than 4 weeks (0.841, 95% CI: 0.436−1.247) than an intervention time less than or equal to four weeks (0.532, 95% CI: 0.370−0.694), and in the group with intervention doses > 5 g (1.116, 95% CI: 0.685−1.546) the counts were higher than those with doses ≤ 5 g (0.521, 95% CI: 0.379−0.663). No differences in effect were found between FOS intervention and comparators in regard to the abundance of other prespecified bacteria or adverse gastrointestinal symptoms. Conclusions: This is the first meta-analysis to explore the effect of FOS on gut microbiota and to evaluate the adverse effects of FOS intake on the gastrointestinal tract. FOS supplementation could increase the number of colonic Bifidobacterium spp. while higher dose (7.5−15 g/d) and longer duration (>4 weeks) showed more distinct effects and was well tolerated.
Keywords: Bifidobacterium spp.; Fructooligosaccharides; gastrointestinal symptoms; gut microbiota.
Conflict of interest statement
The authors declare no conflict of interest.
Figures
Similar articles
-
Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.Cochrane Database Syst Rev. 2022 Feb 1;2(2022):CD014217. doi: 10.1002/14651858.CD014217. Cochrane Database Syst Rev. 2022. PMID: 36321557 Free PMC article.
-
Dietary fiber intervention on gut microbiota composition in healthy adults: a systematic review and meta-analysis.Am J Clin Nutr. 2018 Jun 1;107(6):965-983. doi: 10.1093/ajcn/nqy041. Am J Clin Nutr. 2018. PMID: 29757343
-
Metagenomic Insights into the Effects of Fructooligosaccharides (FOS) on the Composition of Luminal and Mucosal Microbiota in C57BL/6J Mice, Especially the Bifidobacterium Composition.Nutrients. 2019 Oct 12;11(10):2431. doi: 10.3390/nu11102431. Nutrients. 2019. PMID: 31614751 Free PMC article.
-
Effects of maternal probiotic supplementation on breast milk microbiome and infant gut microbiome and health: a systematic review and meta-analysis of randomized controlled trials.Am J Obstet Gynecol MFM. 2023 Nov;5(11):101148. doi: 10.1016/j.ajogmf.2023.101148. Epub 2023 Sep 1. Am J Obstet Gynecol MFM. 2023. PMID: 37660760 Review.
-
Probiotics for the prevention of pediatric antibiotic-associated diarrhea.Cochrane Database Syst Rev. 2015 Dec 22;(12):CD004827. doi: 10.1002/14651858.CD004827.pub4. Cochrane Database Syst Rev. 2015. Update in: Cochrane Database Syst Rev. 2019 Apr 30;4:CD004827. doi: 10.1002/14651858.CD004827.pub5. PMID: 26695080 Updated. Review.
Cited by
-
Evaluation of different glycerol fed-batch strategies in a lab-scale bioreactor for the improved production of a novel engineered β-fructofuranosidase enzyme in Pichia pastoris.World J Microbiol Biotechnol. 2024 May 31;40(7):223. doi: 10.1007/s11274-024-04027-6. World J Microbiol Biotechnol. 2024. PMID: 38819502 Free PMC article.
-
The impact of pre-, pro- and synbiotics supplementation in colorectal cancer treatment: a systematic review.Front Oncol. 2024 May 14;14:1395966. doi: 10.3389/fonc.2024.1395966. eCollection 2024. Front Oncol. 2024. PMID: 38807764 Free PMC article.
-
Xylo-oligosaccharides improve functional constipation by targeted enrichment of Bifidobacterium.Food Sci Nutr. 2023 Nov 27;12(2):1119-1132. doi: 10.1002/fsn3.3827. eCollection 2024 Feb. Food Sci Nutr. 2023. PMID: 38370040 Free PMC article.
-
Prebiotics for depression: how does the gut microbiota play a role?Front Nutr. 2023 Jul 6;10:1206468. doi: 10.3389/fnut.2023.1206468. eCollection 2023. Front Nutr. 2023. PMID: 37485386 Free PMC article. Review.
-
Transforming Psoriasis Care: Probiotics and Prebiotics as Novel Therapeutic Approaches.Int J Mol Sci. 2023 Jul 7;24(13):11225. doi: 10.3390/ijms241311225. Int J Mol Sci. 2023. PMID: 37446403 Free PMC article. Clinical Trial.
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Miscellaneous